Publication for DHCR7 and HMGCS1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	DHCR7	7-dehydrocholesterol reductase	1717			[link]
hsa	HMGCS1	3-hydroxy-3-methylglutaryl-CoA synthase 1	3157

Pubmed ID	Priority	Text
24829397	0.98	HMGCS1, LDLR, DHCR7), and cytokines (IL8, CCL20, CXCL1).
	0.96	HMGCS1, LDLR, DHCR7), and cytokines (IL8, CCL20, CXCL1).
	0.95	HMGCS1, LDLR, DHCR7) and the YAP/Hippo pathway (CTGF, CYR61, SPARC) in addition to luminal/basal markers (KRT14, TP63), DKK1 (Wnt negative regulator), and PHLDA1, an important negative regulator and effector of Aurora A kinase in breast cancer.
22919472	0.98	HMGCS1, DHCR7 and SQLE.
	0.94	3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), 7-dehydrocholesterol reductase (DHCR7), and squalene epoxidase (SQLE).
28933554	0.98	HMGCS1, DHCR7, LSS, and MVD in SUDHL4 cells, with no upregulation seen when human HDL was administered (Figure 2a, Supplemental Figure S5).
	0.91	3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 (HMGCS1), 7-Dehydrocholesterol Reductase (DHCR7), Lanosterol Synthase (LSS), Stearoyl-CoA Desaturase (SCD), and Mevalonate Diphosphate Decarboxylase (MVD).
30321984	0.98	HMGCS1, HMGCR, FDPS, DHCR7, and DHCR24 after treatment of HCC cells with emodin and sorafenib.
24338480	0.97	Hmgcs1, Dhcr7, and Acsl5 protein levels and that only Sar1B:H79G significantly reduced levels of mRNA encoding cholesterol-biosynthetic enzymes (supplemental Table S5).
	0.94	Hmgcs1 and Dhcr7 mRNA levels were significantly lower than in the individual knockdowns (Fig. 4C).
	0.90	Hmgcs1 and Lss protein (Fig. 3D) or increase Dhcr7 protein (Fig. 3D).
	0.89	Hmgcs1, Lss, Dhcr7) and a control enzyme, Acsl5, in stably transfected cells overexpressing Sar1B:H79G (C), Sar1A, and Sar1B (D).
26535575	0.97	HMGCS1, TM7SF2, FDFT1, EBP, FDPS, HMGCR, SQLE, and DHCR7.
	0.96	HMGCS1, TM7SF2, FDFT1, EBP, FDPS, HMGCR, SQLE, and DHCR7.
	0.84	HMGCS1, TMEM97, TM7SF2, FDFT1, ACAT2, EBP, FDPS, HMGCR, SQLE, DHCR7, C14orf1, and INSIG1.
32034223	0.97	HMGCS1, HMGCR, CYP51A1, 7-dehydrocholesterol reductase DHCR7) as well as cholesterol transport (low density lipoprotein receptor LDLR, ATP-binding cassette transporter ABCA1 and ABCG1) expressed in human muscle cells and significantly altered by different exposure to statins.
	0.95	HMGCS1, HMGCR, CYP51A1, DHCR7) and transport (i.e. ABCA1, ABCG1, LDLR).
19400947	0.97	DHCR7 the microarray analysis revealed other genes such as HMGCS1, ACAT2 and LDLR involved in the cholesterol metabolism that were downregulated.
23170111	0.97	HMGCS1, MSMO1, LDLR, DHCR7, SCD, ACAT2, LSS, FASN, MSMO1, SQLE, DHCR24, FDFT1, IDI1, FADS2, ACSS2, EBP, SC5DL, NSDHL and LPIN1), cell cycle regulation (14% of total gene expression changes: CDC2, CDCA8, CDKN3, PRC1, MCM4, CDC20, CDC45L, CCNA1, CCNB2, CCNA2, TOP2A and CDCA7), angiogenesis (5% of total gene expression changes: PGF, ANGPT2, ANGPTL4 and RGS4) and ubiquitin modifications (3% of total gene expression changes: UBE2T, UBE2C and UHRF1).
24625837	0.97	HMGCS1, HMGCR, FDPS, FDFT1 and DHCR7) involved in this pathway.
26418040	0.97	HMGCS1: -4.31(p = 4.49e-11), HMGCR: -2.57(p = 2.9e-10), -2.77(p = 3.13e-10), DHCR7:-2.41(p = 4.82e-8), -2.63(p = 3.84e-9), and SQLE: -2.38(p = 2.09e-8), -2.62(p = 1.00e-6).).
27648077	0.97	3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1), HMG-CoA reductase (HMGCR), farnesyl diphosphate synthase (FDPS), Cytochrome P450 Family 51 Subfamily A Polypeptide 1 (CYP51A1), and 7-dehydrocholesterol reductase (DHCR7) mRNA levels (Figure 5(b)).
29703166	0.97	DHCR7 (catalyzes last step) in addition to NSDHL, MDMO1, EBP, IDI1, CYP51A1, HMGCS1 and SC5D.
19052558	0.95	HMGCS1, DHCR7, FADS1, FADS2, ELOVL4) is decreased to a greater extent in unaffected compared to affected tissue, although, the histological changes (sebaceous gland atrophy) in unaffected tissue are near normal or mild compared to affected tissue.
27595929	0.95	HMGCS1, HMGCR, SQLE, and DHCR7) were found to be suppressed with miR-122 inhibition; however, these gene are likely indirect targets, and thus the exact mechanism by which miR-122 regulates lipid metabolism is still unclear.
31181660	0.95	HMGCS1), 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), Mevalonate kinases (MVK), Phosphomevalonate Kinase (PMVK), Mevalonate Diphosphate Decarboxylase (MVD), 7-Dehydrocholesterol reductase (DHCR7)) (Figure 1c and Figure S1d).
27544699	0.94	3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS1), and 7-dehydrocholesterol reductase (DHCR7).
28027290	0.94	HMGCS1, CYP51A1, DHCR24, DHCR7, STARD4, and NSDHL (S4 Fig);
31261735	0.94	DHCR7, DHCR24, HMGCS1, IDI1, LSS, MVD, MVK, and SQLE, which were all downregulated.
31406127	0.94	HMGCS1, FDFT1, DHCR7 and SC5D), de novo lipogenesis (FASN and ACSS2) and phospholipid dephosphorylation (PLPP3) were upregulated in the hepatic TM6SF2 E167K spheroids, while gluconeogenesis (FBP1) was upregulated in the spheroids and downregulated in humans carrying the E167K risk variant (Fig. 6).
23718831	0.93	HMGCS1, HMGCR, FDPS, FDFT1 and DHCR7) were significantly increased (by 1.5-3.5 fold, Figure 4A), supporting that the elevated expression of these enzymes at protein levels occurs mainly through a transcriptional mechanism via SREBP activation.
24246224	0.90	DHCR7, INSIG1, QPRT, HMGCR, HMGCS1, LDLR, FADS1, FADS2).
31540257	0.89	DHCR7 (14.7/13.5), DHCR24 (17.3/16.8), FDFT1 (9.6/9.9), HMGCR (3 transcripts, 17.1/16.9, 14.2/14.8, and 4.1/3.7), HMGCS1 (16.8/16.5), HMGCS2 (9.8/10.4), LCAT (7.7/7.7), LSS (8.1/7.5), MSMO1 (16.6/16.2), SOAT1 (17.2/17.5), SOAT2 (5.1/4.9), and SQLE (13.5/12.9).
17052361	0.88	3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) (5.6, p = 0.000009), fatty acid synthase (FASN) (5.4, p = 0.000008), 7-dehydrocholesterol reductase (DHCR7) (4.3, p = 0.000008), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (3.1, p = 0.00001), sterol-C5-desaturase like (SC5DL) (3.1, p = 0.00001), acetyl-CoA acetyltransferase 2 (also termed acetoacetyl-CoA thiolase; ACAT2) (3.0, p = 0.00009), low density lipoprotein receptor (LDLR) (2.8, p = 0.00001) and farnesyl diphosphate synthase (FDPS) (2.8, p = 0.000009).
	0.86	HMGCS1, FDPS, SC5DL, DHCR7, LDLR, FASN and SCD1) in four CNS-relevant human cell lines.
	0.51	HMGCS1, HMGCR, FDPS, SC5DL and DHCR7; see legend to Fig. 1 for complete names), cholesterol transport (LDLR) and fatty acid biosynthesis (FASN and SCD1).
30700717	0.88	HMGCS1, FDFT1 and DHCR7 were downregulated at the mRNA level in a dose-dependent manner when cells were exposed to 25-HC for the 36 h incubation period (Fig. 4a).
26535009	0.82	HMGCS1, DHCR7, DHCR24, LDLR, FDFT1, FDPS, IDI1, MVD, SQLE, LSS, NSDHL, SC5DL, INSIG1, ACLY, and ACSS2 (see fig. S1 for full list).
18070364	0.79	HMGCS1, HMGCR, IDI1, FDPS, FDFT1, NSDHL, EBP, DHCR7, INSIG1, FADS1 were upregulated by P4 exposure (Additional File 2).
30237397	0.73	DHCR7, FDFT1, HMGCR, HMGCS1, HSD17B7, INSIG1, LSS, MSMO1, SQLE, LDLR, and ACAT2) (Fig. 6a), which is consistent with the mechanism of action of melittin.